BiotechTube
CoA Therapeutics

CoA Therapeutics

Cambridge, United States· Est.
coatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

CoA Therapeutics is a clinical-stage biotech developing small-molecule activators of pantothenate kinase (PanK) to restore CoA levels in severe metabolic and neurodegenerative disorders. Its lead program, BBP-671, is in Phase 1 development for PKAN and organic acidurias, with initial data showing promise in healthy volunteers. The company is a subsidiary of BridgeBio Pharma, leveraging its parent's operational and development expertise to advance treatments for diseases with high unmet need.

Rare Genetic DiseasesMetabolic DisordersNeurodegeneration

Technology Platform

Small-molecule allosteric activators of pantothenate kinase (PanK) designed to overcome feedback inhibition and restore Coenzyme A (CoA) biosynthesis in diseases of CoA sequestration.

Funding History

2
Total raised:$105M
Series B$75M
Series A$30M

Opportunities

First-to-market potential in PKAN and first-in-class pathogenic therapy for organic acidurias represent high-value orphan drug opportunities.
The CoA modulation platform has potential for expansion into other, more prevalent metabolic disorders where CoA dysregulation is implicated, such as Type 2 diabetes.

Risk Factors

High clinical risk associated with novel mechanism in severe diseases, including potential failure to demonstrate efficacy in the central nervous system for PKAN or meaningful clinical benefit in organic acidurias.
Dependency on parent company BridgeBio for funding and strategic direction.

Competitive Landscape

In PKAN, competition includes gene therapy and other novel therapeutic approaches, though no approved therapies exist. For organic acidurias, several companies are developing enzyme replacement therapies, gene therapies, and mRNA treatments, creating a more crowded but still high-need landscape.

More companies in Small Molecule Drugs →More companies in United States →